Connor, Clark & Lunn Investment Management (CC&L)’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio TTPH Stock Details TTPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-550	Closed	-$42K	–	1035
2016 Q3	$42K	Sell	550 -325	-37%	-$26K	﹤0.01%	807
2016 Q2	$75K	Sell	875 -200	-19%	-$18.3K	﹤0.01%	817
2016 Q1	$100K	Buy	+1,075	New	+$107K	﹤0.01%	769

Other funds holding TTPH

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s TTPH Position: Q4 2016 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q4 2016, closing a stake of 550 shares — an estimated $42K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in TTPH in Q1 2016 and held it in 3 quarters. The position peaked at $100K in Q1 2016. 91 funds tracked by Wall St. Rank hold TTPH as of Q4 2016.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 550 Tetraphase Pharmaceuticals, Inc. shares in Q4 2016, an estimated $42K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Tetraphase Pharmaceuticals, Inc. in Q1 2016 and held it in 3 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Tetraphase Pharmaceuticals, Inc. position peaked at $100K in Q1 2016.
91 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q4 2016.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2016, filed 13 Feb 2017.